Dupilumab use in atopic dermatitis and beyond in skin diseases

Kayla Fourzali, Rachel Shireen Golpanian, Gil Yosipovitch

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Atopic dermatitis (AD) is a chronic inflammatory condition that affects 5-10% of adults and 9-18% of children and its pathology is rooted in the Th-2-mediated immune response. Dupilumab is a fully human IgG4 monoclonal antibody that targets the IL-4 receptor alpha subunit that is endogenously bound by the Th-2 cytokines IL-4 and IL-13. Successful clinical trials of dupilumab showing marked improvements in clinical signs of AD, patient reported symptoms and quality of life measures led to its approval for clinical use for moderate-to-severe AD in 2017. This review details the current body of evidence on the drug's mechanism of action, pharmacology, clinical efficacy and safety as well as post market and real world use.

Original languageEnglish (US)
Pages (from-to)1221-1235
Number of pages15
Issue number17
StatePublished - Dec 2020


  • atopic dermatitis
  • clinical trials
  • cytokines
  • dupilumab
  • monoclonal antibody
  • pruritus

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology


Dive into the research topics of 'Dupilumab use in atopic dermatitis and beyond in skin diseases'. Together they form a unique fingerprint.

Cite this